Webjcog0202：「限局型小細胞肺癌に対する、エトポシド＋シスプラチン（ep）と胸部放射線多分割 照射同時併用療法に引き続く、イリノテカン＋シスプラチン（ip）とep を比較 … Web1 gen 2014 · As far as we are aware, JCOG0202 is the first randomised trial investigating the efficacy of irinotecan plus cisplatin in patients with limited-stage disease. The hypothesis that irinotecan plus cisplatin could improve overall survial for these patients compared with etoposide plus cisplatin was refuted.

202 2nd St S, Coggon, IA 52218 Redfin

WebPer valutare il ruolo di 3 cicli di irinotecan e cisplatino per i pazienti con stadio limitato carcinoma polmonare a piccole cellule che ha ricevuto un ... Registro delle prove … WebEtoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated … ghasem ghods net worth

History of Japan Clinical Oncology Group (JCOG) Lung Cancer …

Web28 set 2024 · Background. Small-cell lung cancer (SCLC) has poor prognosis and is prone to drug resistance. It is necessary to search for possible influencing factors for SCLC chemotherapy insensitivity. Therefore, we proposed an mRNA network to track the chemotherapy insensitivity in SCLC. Methods. Six samples of patients with SCLC … Web28 lug 2024 · Objective: Chemotherapy with irinotecan plus cisplatin has shown promise in chemo-naïve small-cell lung cancer (SCLC) patients. However, irinotecan treatment for relapsed or refractory SCLC has not been adequately evaluated. This phase II study evaluated the appropriate treatment schedule of irinotecan as a single agent. This study … http://www.jcog.jp/document/0202.pdf ghase bank.com